JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
Alexandra Dusa, Céline Mouton, Christian Pecquet et al. · 2010
Read JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors by Alexandra Dusa, Céline Mouton, Christian Pecquet et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011157.txt.
Description
Dusa, Mouton, Pecquet and colleagues pinpointed a blood cancer target in PLOS ONE in 2010. A mutant form of a signaling protein stays switched on and drives some blood cancers. The mutant needs help from a second region of the same protein to stay active, and the team located a key spot in that region.
That spot, a single building block in a helper domain, proved required for constant activity. A drug aimed there could block the mutant while sparing normal signaling proteins. Such precise blockers promise fewer side effects than broad drugs. The finding turns a structural detail into a concrete drug design goal.
Catalog record
| CREATOR | Alexandra Dusa, Céline Mouton, Christian Pecquet et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011157